FDA Flags GLP-1 Eye Risks

It's Benzinga, bringing Wall Street to Main Street. The U.S. Food and Drug Administration is requiring new safety warnings on all GLP-1 drugs over a potential increased risk of a rare eye condition that can cause permanent vision loss, according to CNBC. The condition, known as non-arteritic anterior ischemic optic neuropathy, or NAION, has been reported for all marketed GLP-1 products, though a causal relationship has not been established. An FDA review of 126 clinical trials involving more than 134,000 patients found 6.4 cases per 100,000 patient years among GLP-1 users, compared with 3.8 among other patients. Ozempic and Wegovy maker Novo Nordisk said the data do not establish a causal relationship and expressed confidence in the benefit-risk profile of its GLP-1 drugs. CNBC contacted Mounjaro, Zepbound, and Zepbound maker Eli Lilly for comment. City analysts expect the warnings to have limited impact on GLP-1 uptake, citing the condition's rarity and the drug's benefits. For all things money, visit Benzinga.com.